Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Ophthalmology Physician in Mission Hills, CA
NPI: 1073565560Primary Employer
California Eye Care Managed Eye Care Specialists a Medical Group Inc.
californiaeyespecialists.com
HQ Phone
Get M.D. Robert's Phone Numberphone_androidMobile
Get M.D. Robert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1990 - 2026
American Board of Ophthalmology
Ophthalmology
UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye Institutes
Residency • Ophthalmology
1991 - 1994
Maimonides Medical Center
Internship • Transitional Year
1989 - 1990
Autonomous Metropolitan University Xochimilco
Medical School
Until 1987
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 246 | 318 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 206 | 345 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 89 | 89 |
| 4 | 92134Diagnostic imaging of retina | 63 | 116 |
| 5 | 92014Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 46 | 47 |
Authors: Charles Slonim, Jason Bacharach, Michael Korenfeld, David Wirta
Journal: Clin Ophthalmol
Publication Date: 2021-06-25
Association of Oxymetazoline Hydrochloride, 0.1%, Solution Administration With Visual Field in Acquired Ptosis: A Pooled Analysis of 2 Randomized Clinical Trials.
Authors: Charles Slonim, Michael Korenfeld, David Wirta
Publication Date: 2020-11
Lead Sponsor: Surface Ophthalmics, Inc.
Intervention / Treatment: DRUG: Lifitegrast 5% Ophthalmic Solution, DRUG: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), DRUG: Mycophenolic Acid 0.1%, DRUG: Mycophenolic Acid 0.3%, DRUG: Betamethasone Sodium Phosphate 0.01%, DRUG: Placebo Comparator: Vehicle, DRUG: Cyclosporine 0.05% Ophthalmic Emulsion
Lead Sponsor: Kala Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: Vehicle of KPI-121 1.0%, DRUG: KPI-121 0.25%, DRUG: KPI-121 1.0%, DRUG: Vehicle of KPI-121 0.25%